AI assistant
NUFORMIX PLC Board/Management Information 2021
4941_mang_2021-07-22_47b9a1d5-3269-4f1f-8853-6d4b1b2b17c0.html
Board/Management Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 0410G
Nuformix PLC
22 July 2021
REACH - Non-regulatory announcement
Nuformix plc
("Nuformix" or the "Company")
Letter to shareholders re: Dr Anne Brindley
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that further to the RNS issued yesterday on the departure of Dr Anne Brindley as CEO, the Company has issued a letter to shareholders. The letter can be viewed here: https://nuformix.com/document-center/
Enquiries:
| Nuformix plc | via Walbrook | ||||
| Dr Alastair Riddell, Non-Executive Chairman | |||||
| Dr Anne Brindley, CEO | |||||
| Allenby Capital Limited | +44 (0) 20 3328 5656 | ||||
| Nick Athanas / George Payne (Corporate Finance) | |||||
| Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) | |||||
| Walbrook PR | [email protected] or +44 (0)20 7933 8780 | ||||
| Anna Dunphy / Paul McManus / Kiki Zaccagnini | Tel: +44 (0)7876 741 001 / +44 (0)7980 541 893 | ||||
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NRAEFLFLFDLEBBB